Advertisement
Advertisement
U.S. markets close in 1 hour 53 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.53-0.82 (-1.73%)
As of 02:07PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close47.35
Open47.07
Bid46.75 x 1000
Ask46.85 x 800
Day's Range46.19 - 47.92
52 Week Range27.65 - 103.92
Volume308,575
Avg. Volume1,016,295
Market Cap4.766B
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-4.13
Earnings DateFeb 21, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est79.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Guardant Health, Inc.
    Analyst Report: Guardant Health, Inc.Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
Advertisement
Advertisement